These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 3296130)

  • 1. Hereditary tyrosinemia type I--an overview.
    Kvittingen EA
    Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase.
    Kvittingen EA; Brodtkorb E
    Scand J Clin Lab Invest Suppl; 1986; 184():35-40. PubMed ID: 3473612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosinaemia type I--an update.
    Kvittingen EA
    J Inherit Metab Dis; 1991; 14(4):554-62. PubMed ID: 1749221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein.
    Kvittingen EA; Rootwelt H; van Dam T; van Faassen H; Berger R
    Pediatr Res; 1992 Jan; 31(1):43-6. PubMed ID: 1594329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-induced correction of the genetic defect in tyrosinemia type I.
    Kvittingen EA; Rootwelt H; Berger R; Brandtzaeg P
    J Clin Invest; 1994 Oct; 94(4):1657-61. PubMed ID: 7929843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.
    Poudrier J; Lettre F; Scriver CR; Larochelle J; Tanguay RM
    Mol Genet Metab; 1998 Jun; 64(2):119-25. PubMed ID: 9705236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.
    Kvittingen EA; Rootwelt H; Brandtzaeg P; Bergan A; Berger R
    J Clin Invest; 1993 Apr; 91(4):1816-21. PubMed ID: 8473520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine and its catabolites: from disease to cancer.
    Tanguay RM; Jorquera R; Poudrier J; St-Louis M
    Acta Biochim Pol; 1996; 43(1):209-16. PubMed ID: 8790725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosinemia: the Quebec experience.
    Paradis K
    Clin Invest Med; 1996 Oct; 19(5):311-6. PubMed ID: 8889268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).
    Tanguay RM; Valet JP; Lescault A; Duband JL; Laberge C; Lettre F; Plante M
    Am J Hum Genet; 1990 Aug; 47(2):308-16. PubMed ID: 2378356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.
    Phaneuf D; Lambert M; Laframboise R; Mitchell G; Lettre F; Tanguay RM
    J Clin Invest; 1992 Oct; 90(4):1185-92. PubMed ID: 1401056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic tyrosinemias.
    Scott CR
    Am J Med Genet C Semin Med Genet; 2006 May; 142C(2):121-6. PubMed ID: 16602095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme defect in a case of tyrosinemia type I, acute form.
    Furukawa N; Kinugasa A; Seo T; Ishii T; Ota T; Machida Y; Inoue F; Imashuku S; Kusunoki T; Takamatsu T
    Pediatr Res; 1984 May; 18(5):463-6. PubMed ID: 6145143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterozygosity for an exon 12 splicing mutation and a W234G missense mutation in an American child with chronic tyrosinemia type 1.
    Hahn SH; Krasnewich D; Brantly M; Kvittingen EA; Gahl WA
    Hum Mutat; 1995; 6(1):66-73. PubMed ID: 7550234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the enzymic defects in hereditary tyrosinemia.
    Lindblad B; Lindstedt S; Steen G
    Proc Natl Acad Sci U S A; 1977 Oct; 74(10):4641-5. PubMed ID: 270706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I.
    Grompe M; al-Dhalimy M
    Hum Mutat; 1993; 2(2):85-93. PubMed ID: 8318997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prenatal diagnosis of hereditary tyrosinemia by determination of fumarylacetoacetase in cultured amniotic fluid cells.
    Kvittingen EA; Steinmann B; Gitzelmann R; Leonard JV; Andria G; Børresen AL; Mossman J; Micara G; Lindblad B
    Pediatr Res; 1985 Apr; 19(4):334-7. PubMed ID: 4000758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase.
    Rootwelt H; Chou J; Gahl WA; Berger R; Coşkun T; Brodtkorb E; Kvittingen EA
    Hum Genet; 1994 Jun; 93(6):615-9. PubMed ID: 8005583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The metabolic basis of the hyperphenylalaninemias and tyrosinemia].
    Shintaku H
    Nihon Rinsho; 1992 Jul; 50(7):1542-7. PubMed ID: 1357201
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.